Bronchopulmonary Dysplasia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Bronchopulmonary Dysplasia – Pipeline Review, H2 2016’, provides an overview of the Bronchopulmonary Dysplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia

The report reviews pipeline therapeutics for Bronchopulmonary Dysplasia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bronchopulmonary Dysplasia therapeutics and enlists all their major and minor projects

The report assesses Bronchopulmonary Dysplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Airway Therapeutics LLC

Chiesi Farmaceutici SpA

Insmed Incorporated

MediPost Co., Ltd.

Meridigen Biotech Co., Ltd.

Syntrix Biosystems, Inc.

Therabron Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Bronchopulmonary Dysplasia Overview 7

Therapeutics Development 8

Pipeline Products for Bronchopulmonary Dysplasia - Overview 8

Bronchopulmonary Dysplasia - Therapeutics under Development by Companies 9

Bronchopulmonary Dysplasia - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Bronchopulmonary Dysplasia - Products under Development by Companies 13

Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development 14

Airway Therapeutics LLC 14

Chiesi Farmaceutici SpA 15

Insmed Incorporated 16

MediPost Co., Ltd. 17

Meridigen Biotech Co., Ltd. 18

Syntrix Biosystems, Inc. 19

Therabron Therapeutics, Inc. 20

Bronchopulmonary Dysplasia - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

AT-100 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

budesonide - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CG-100 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Drugs for Bronchopulmonary Dysplasia - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

mecasermin rinfabate - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Pneumostem - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

R-190 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

R-801 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

R-901 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

R-908 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

R-911 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Stem Cell Therapies for Bronchopulmonary Dysplasia - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

SX-576 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

vitamin A palmitate - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Bronchopulmonary Dysplasia - Dormant Projects 53

Bronchopulmonary Dysplasia - Discontinued Products 54

Bronchopulmonary Dysplasia - Product Development Milestones 55

Featured News & Press Releases 55

Jun 02, 2016: Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants 55

May 25, 2016: Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants 55

May 03, 2016: MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease 56

Apr 28, 2016: Therabron Therapeutics Receives FDA Fast Track Designation for rhCC10 for the Prevention of Chronic Lung Disease Related to Premature Birth 56

Apr 13, 2016: Therabron Therapeutics Receives Notice of Allowance for New Patent Supporting the Recombinant CC10 Technology Platform 57

Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate 57

Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial 58

Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform 59

Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program 59

May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia 60

Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung 60

Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial 61

Jul 29, 2014: Lung disease stem cell drug designated ‘orphan drug in development stage’ 61

Feb 06, 2014: Stem cells to treat lung disease in preterm infants 62

Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem 62

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

List of Tables

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Bronchopulmonary Dysplasia – Pipeline by Airway Therapeutics LLC, H2 2016 14

Bronchopulmonary Dysplasia – Pipeline by Chiesi Farmaceutici SpA, H2 2016 15

Bronchopulmonary Dysplasia – Pipeline by Insmed Incorporated, H2 2016 16

Bronchopulmonary Dysplasia – Pipeline by MediPost Co., Ltd., H2 2016 17

Bronchopulmonary Dysplasia – Pipeline by Meridigen Biotech Co., Ltd., H2 2016 18

Bronchopulmonary Dysplasia – Pipeline by Syntrix Biosystems, Inc., H2 2016 19

Bronchopulmonary Dysplasia – Pipeline by Therabron Therapeutics, Inc., H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Bronchopulmonary Dysplasia – Dormant Projects, H2 2016 53

Bronchopulmonary Dysplasia – Discontinued Products, H2 2016 54

List of Figures

List of Figures

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Targets, H2 2016 22

Number of Products by Stage and Targets, H2 2016 22

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports